Funding for this research was provided by:
KWF Kankerbestrijding (KWF VU 2012−5708)
European Research Council (ERC advanced 2012‐AdG, proposal 322986; Mass‐Care)
Text and Data Mining valid from 2018-06-07
Received: 7 November 2017
Accepted: 29 May 2018
First Online: 7 June 2018
Ethics approval and consent to participate
: This study was approved by the Institutional Review Boards of the VU University Medical Center and Antoni van Leeuwenhoek Hospital. All samples were used in an anonymous fashion in accordance with the “Code for Proper Secondary Use of Human Tissues in the Netherlands” as formulated by the Dutch Federation of Medical Scientific Organizations (ExternalRef removed) [CitationRef removed].
: DAMH occasionally serves on the scientific advisory board of Pfizer and Bristol-Meyer Squibb and has been on the speakers’ bureau of Qiagen. PJFS, RDMS, CJLMM, and DAMH are minority stakeholders of Self-screen B.V., a spin-off company of VU University Medical Center; and since September 2017, CJLMM is director of Self-screen B.V., which holds patents related to the work. PJFS has received speakers’ bureau honoraria from Roche, Qiagen, Gen-Probe, Abbott, and Seegene. He is consultant for Crucell Holland B.V. CJLMM has participated in the sponsored speaker’s bureau of Merck and Qiagen and served occasionally on the scientific advisory board of Qiagen and Merck. CJLMM owns a small number of shares of Qiagen, has occasionally been consultant for Qiagen, and until April 2016 was a minority shareholder of Diassay B.V. No potential conflicts of interest were disclosed by the other authors.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.